Bandelow, Borwin http://orcid.org/0000-0003-2511-3768
Werner, Antonia M.
Kopp, Ina
Rudolf, Sebastian
Wiltink, Jörg
Beutel, Manfred E.
Funding for this research was provided by:
Georg-August-Universität Göttingen
Article History
Received: 18 May 2021
Accepted: 27 August 2021
First Online: 5 October 2021
Declarations
:
: All participants in the guideline panel have declared their conflicts of interest (e.g., having received lecture honoraria from drug manufacturers or being a leading member of a group which advocates a particular form psychotherapy school). The guideline committee undertook every effort to base its recommendations exclusively on objective evaluation of the scientific evidence. Participants with a relevant conflict of interest abstained when recommendations on the treatment in question came to vote. In the past 36 months, Dr Bandelow has been on the speakers’ board for Janssen, Lilly, Pfizer, Roche and Schwabe on the advisory board for Cannaxan, Lundbeck and Pfizer. Dr Werner, Dr Kopp, Dr Rudolf, Dr Wiltink and Dr Beutel declare that no conflicts of interest exist.